According to TipRanks.com, Richter is a 4-star analyst with an average return of 8.8% and a 42.9% success rate. Richter covers the Healthcare sector, focusing on stocks such as Ultragenyx ...

Unlike other vaccines, mRNA vaccines can be made very quickly. They can also be easily modified to fight new viruses and ...

The U.S. health secretary ordered an end to new mRNA development efforts just after UTMB published new research showing its ...

With vaccine revenue crumbling and layoffs in full swing, is Moderna’s slimmed-down strategy a smart move or a red flag for ...

The Trump Administration said this week it is pulling half a billion dollars from U.S. government-funded research projects to create new mRNA vaccines. Experts say this could potentially impact mRNA ...

Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the ...

In a report released yesterday, Cory Kasimov from Evercore ISI maintained a Hold rating on Moderna, with a price target of $32.00. The company’s shares closed yesterday at $27.64. Take advantage of ...

The U.S. health department is canceling or scaling back 22 BARDA-backed mRNA projects worth nearly $500 million, shifting ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 7.1% in the afternoon session after the company trimmed the upper ...

The Department of Health and Human Services (HHS) is winding down its mRNA vaccine development activities under the ...

US Health and Human Services is “winding down” its mRNA vaccine development and will instead fund other vaccine platforms ...